During the past decade, Southeast Renal Research Institute conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 12 clinical trials were completed, i.e. on average, 80% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 5 clinical trials were completed. i.e. 71.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Southeast Renal Research Institute" #1 sponsor was "Goldfinch Bio, Inc." with 3 trials, followed by "Keryx Biopharmaceuticals" with 3 trials sponsored, "Southeast Renal Research Institute" with 3 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored and "Gilead Sciences" with 2 trials sponsored. Other sponsors include 10 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Southeast Renal Research Institute" #1 collaborator was "Collaborative Study Group (CSG)" with 1 trials as a collaborator, "Dialysis Clinic, Inc." with 1 trials as a collaborator, "Hospira, now a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "Mallinckrodt" with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Southeast Renal Research Institute" are "Chronic Kidney Disease" (6 trials), "Chronic Renal Failure" (3 trials), "Hyperphosphatemia" (3 trials), "Uremic Pruritus" (3 trials) and "Chronic Renal Insufficiency" (2 trials). Many other conditions were trialed in "Southeast Renal Research Institute" in a lesser frequency.

Most popular intervention types in "Southeast Renal Research Institute" are "Drug" (25 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "GFB-887" (2 trials), "ferric citrate" (2 trials), "1.25 g PA21 (250 mg iron)" (1 trials) and "10.0 g PA21 (2,000 mg iron)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Southeast Renal Research Institute" are 28 trials for "All" genders.

Currently, there are NaN active trials in "Southeast Renal Research Institute". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in Southeast Renal Research Institute, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Southeast Renal Research Institute, 2 "Phase 1" clinical trials were conducted, 18 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".